Precigen
PGEN
137 hedge funds and large institutions have $85.6M invested in Precigen in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 45 reducing their positions, and 19 closing their positions.
400% more call options, than puts
Call options by funds: $85K | Put options by funds: $17K
1.94% more ownership
Funds ownership: 23.72% → 25.65% (+1.9%)
1% less capital invested
Capital invested by funds: $86M → $85.6M (-$450K)
1% less funds holding
Funds holding: 138 → 137 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
24% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Patient Capital Management
Baltimore,
Maryland
|
+$2.62M |
| 2 |
Morgan Stanley
New York
|
+$1.83M |
| 3 |
Millennium Management
New York
|
+$1.67M |
| 4 |
BlackRock
New York
|
+$780K |
| 5 |
D.E. Shaw & Co
New York
|
+$418K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$950K |
| 2 |
FWC
First Washington Corp
Seattle,
Washington
|
-$918K |
| 3 |
MP
MSD Partners
New York
|
-$711K |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$582K |
| 5 |
Renaissance Technologies
New York
|
-$520K |
PGEN Hedge Fund Activity: Q4 2023 in Review
137 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Precigen (PGEN) for Q4 2023, worth a combined $85.6M — down 0.52% from $86M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PGEN and 18 opened new positions — a net loss of 1 holder — while 45 trimmed existing stakes and 34 added.
The largest buyer was Patient Capital Management, adding an estimated $2.62M. The largest seller was GMT Capital, exiting entirely with an estimated $950K sold.
- 137 institutional investors held Precigen (PGEN) as of Q4 2023, down from 138 in Q3 2023.
- Funds reported $85.6M of Precigen stock for Q4 2023, down 0.52% quarter-over-quarter.
- 18 funds opened new Precigen positions in Q4 2023 and 19 closed out, a net change of -1 holder.
- The largest Precigen buyer in Q4 2023 was Patient Capital Management, an estimated $2.62M added.
- The largest Precigen seller in Q4 2023 was GMT Capital, an estimated $950K sold.
Based on aggregated 13F filings for Q4 2023.